CordenPharma, a biotech and pharmaceutical CDMO, is set to invest over €1 billion over the next three years to expand its peptide manufacturing capabilities across Europe and the US.

Over €500 million of the investment will go towards building a new facility in Basel, Switzerland. The site will feature advanced automation and cutting-edge peptide production technology, with over 5,000 L of SPPS reactor capacity to support various scales of GLP-1 and non-GLP-1 peptide production. Construction will take place between 2025 and 2027, with operations beginning in 2028.

In the US, CordenPharma’s Colorado site will also undergo significant expansion, more than doubling its current SPPS reactor capacity by adding 25,000 L, reaching a total of over 42,000 L by 2028. Once complete, both sites will boost the company’s global production capabilities, reinforcing its position as a leading peptide manufacturing partner.